Cargando…
Association of Programmed Death-Ligand 1 Expression with Aggressive Histological Types of Thyroid Carcinoma
INTRODUCTION: Immunohistochemical expression of programmed death-ligand 1 (PD-L1) has become a biomarker to predict the usefulness of cancer immunotherapy using PD-1/PD-L1 blockade in a variety of advanced-stage tumours. This emerging biomarker may serve to generate novel therapies for aggressive th...
Autores principales: | Harahap, Agnes Stephanie, Lay, Fanny Kamarudy, Kodariah, Ria, Wongkar, Fresia Juwitasari, Ham, Maria Francisca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793731/ https://www.ncbi.nlm.nih.gov/pubmed/36583030 http://dx.doi.org/10.2147/CMAR.S392475 |
Ejemplares similares
-
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
por: Chowdhury, Subrata, et al.
Publicado: (2016) -
The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
por: Rajabto, Wulyo, et al.
Publicado: (2022) -
Clinicopathological Profile of Thyroid Carcinoma in Young Patients: An Indonesian Single-Center Study
por: Harahap, Agnes Stephanie, et al.
Publicado: (2022) -
Thyroid hemiagenesis associated with Hurthle cell carcinoma: A case report
por: Kartini, Diani, et al.
Publicado: (2021) -
MUM1 Expression versus Hans Algorithm to Predict Prognosis in Indonesian Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP
por: Irawan, Cosphiadi, et al.
Publicado: (2022)